Aprea Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APRE Nasdaq 2830 aprea.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aprea Therapeutics, Inc.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - Aug 4th, 2026 6:25 am
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - Jul 30th, 2026 6:00 am
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - Jun 1st, 2026 6:00 am
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - May 13th, 2026 4:30 am
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls - May 7th, 2026 7:45 am
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Apr 21st, 2026 8:15 am
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - Apr 1st, 2026 6:30 am
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement - Mar 30th, 2026 6:01 am
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - Mar 30th, 2026 6:00 am
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - Mar 16th, 2026 6:00 am
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - Feb 18th, 2026 6:00 am
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 17th, 2026 6:00 am
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - Feb 12th, 2026 6:30 am
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - Feb 4th, 2026 6:30 am
BC-Most Active Stocks - Jan 30th, 2026 8:30 am
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - Jan 29th, 2026 6:27 am
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Jan 29th, 2026 6:25 am
New Strong Sell Stocks for January 19th - Jan 19th, 2026 3:14 am
New Strong Sell Stocks for Jan. 14 - Jan 14th, 2026 2:21 am
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - Dec 18th, 2025 6:30 am